S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Italy's Lake Garda shrinks to near-historic low amid drought
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:ARDX

Ardelyx - ARDX Stock Forecast, Price & News

$0.93
+0.03 (+3.34%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.89
$0.94
50-Day Range
$0.51
$0.93
52-Week Range
$0.49
$1.92
Volume
1.99 million shs
Average Volume
1.56 million shs
Market Capitalization
$143.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.20

Ardelyx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
420.3% Upside
$4.83 Price Target
Short Interest
Bearish
7.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.98
Upright™ Environmental Score
News Sentiment
0.42mentions of Ardelyx in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$153,157 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.70) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

663rd out of 1,117 stocks

Pharmaceutical Preparations Industry

331st out of 550 stocks

ARDX stock logo

About Ardelyx (NASDAQ:ARDX) Stock

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Analysts Set New Price Targets

ARDX has been the topic of several research analyst reports. Cantor Fitzgerald cut Ardelyx from an "overweight" rating to a "neutral" rating and reduced their target price for the company from $7.00 to $1.00 in a research note on Friday, May 6th. StockNews.com lowered Ardelyx from a "hold" rating to a "sell" rating in a research report on Saturday, August 6th. Piper Sandler reduced their target price on shares of Ardelyx from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 18th. Finally, Wedbush reissued a "neutral" rating on shares of Ardelyx in a research report on Friday, August 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $4.83.

Ardelyx Trading Up 3.9 %

NASDAQ:ARDX traded up $0.03 on Friday, reaching $0.93. 1,991,414 shares of the stock traded hands, compared to its average volume of 1,563,752. The company has a market capitalization of $143.66 million, a price-to-earnings ratio of -0.82 and a beta of 1.84. Ardelyx has a 12 month low of $0.49 and a 12 month high of $1.92. The company's fifty day simple moving average is $0.68 and its 200 day simple moving average is $0.78.

Ardelyx (NASDAQ:ARDX - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.19) EPS for the quarter, meeting analysts' consensus estimates of ($0.19). Ardelyx had a negative net margin of 2,594.88% and a negative return on equity of 191.74%. During the same quarter in the previous year, the business earned ($0.45) EPS. Equities analysts anticipate that Ardelyx will post -0.7 EPS for the current fiscal year.

Insider Activity

In other news, insider Susan Rodriguez sold 43,920 shares of Ardelyx stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $0.65, for a total value of $28,548.00. Following the completion of the sale, the insider now directly owns 289,593 shares in the company, valued at $188,235.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Michael Raab sold 103,624 shares of the company's stock in a transaction on Monday, June 6th. The stock was sold at an average price of $0.65, for a total transaction of $67,355.60. Following the completion of the sale, the chief executive officer now owns 668,826 shares in the company, valued at $434,736.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Susan Rodriguez sold 43,920 shares of the firm's stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $0.65, for a total value of $28,548.00. Following the completion of the transaction, the insider now directly owns 289,593 shares in the company, valued at $188,235.45. The disclosure for this sale can be found here. Insiders have sold a total of 235,185 shares of company stock valued at $153,157 over the last ninety days. 6.00% of the stock is currently owned by corporate insiders.

Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Stock News Headlines

Wedbush Reiterates Neutral Rating for Ardelyx (NASDAQ:ARDX)
StockNews.com Downgrades Ardelyx (NASDAQ:ARDX) to Sell
Analysts Set Ardelyx, Inc. (NASDAQ:ARDX) Target Price at $4.83
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Company Calendar

Last Earnings
8/04/2022
Today
8/13/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARDX
Employees
86
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.83
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+244.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-158,160,000.00
Net Margins
-2,594.88%
Pretax Margin
-2,594.71%

Debt

Sales & Book Value

Annual Sales
$10.10 million
Book Value
$0.34 per share

Miscellaneous

Free Float
145,358,000
Market Cap
$143.66 million
Optionable
Optionable
Beta
1.84














ARDX Stock - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price forecast for 2022?

6 Wall Street analysts have issued 1-year target prices for Ardelyx's stock. Their ARDX share price forecasts range from $1.00 to $13.00. On average, they anticipate the company's share price to reach $4.83 in the next year. This suggests a possible upside of 420.3% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2022?

Ardelyx's stock was trading at $1.10 on January 1st, 2022. Since then, ARDX shares have decreased by 15.5% and is now trading at $0.9290.
View the best growth stocks for 2022 here
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19). Ardelyx had a negative trailing twelve-month return on equity of 191.74% and a negative net margin of 2,594.88%. During the same quarter in the previous year, the business earned ($0.45) earnings per share.

What other stocks do shareholders of Ardelyx own?

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different retail and institutional investors. Top institutional shareholders include Prosight Management LP (1.40%), Ikarian Capital LLC (1.09%), Renaissance Technologies LLC (0.14%), Franklin Resources Inc. (0.13%), Group One Trading L.P. (0.00%) and Northern Trust Corp (0.13%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $0.93.

How much money does Ardelyx make?

Ardelyx (NASDAQ:ARDX) has a market capitalization of $143.66 million and generates $10.10 million in revenue each year. The biopharmaceutical company earns $-158,160,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.

This page (NASDAQ:ARDX) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.